Chondrongenesis promotors and indolin-2-one derivatives

Details Chondrongenesis promotors and indolin-2-one derivatives Chondrongenesis promotors and indolin-2-one derivatives

2001-09-21

2002-12-31

Powers, Fiona T. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S419000, C548S483000, C548S486000

Reexamination Certificate

active

06500854

ABSTRACT:

TECHNICAL FIELD
The present invention relates to pharmaceutically useful indolin-2-one derivatives or their salts, and to chondrogenesis promoters, cartilage repair agents and cartilage diagnostic reagents containing the indolin-2-one derivatives or their pharmaceutically acceptable salts.
BACKGROUND ART
Cartilage in the body generally consists of chondrocytes and fibrocytes, which are specialized connective tissue cells, and an amorphous gel-like matrix in which they are embedded, and it forms a part of the supportive tissue of the body.
In warm-blooded animals including humans, cartilage forms the skeleton, joints, tracheae, auricula, nose and the like. That is, it performs a central role in functions that are indispensable to the survival of warm-blooded animals, including acting as a template for bone during growth (growth cartilage), and contributing to smooth joint movement (articular cartilage), respiration (tracheal cartilage, nasal cartilage) and hearing (auricular cartilage). Thus, degeneration or destruction of these types of cartilage causes various degrees of detriment to the body depending on the site and severity of degeneration or destruction.
For example, among the aforementioned functions in which cartilage plays a role (growth, joints, respiration, hearing, etc.), the smooth movement of joints is particularly impaired by degeneration or destruction of articular cartilage in such conditions as chronic rheumatoid arthritis or osteoarthritis. Degeneration or destruction of articular cartilage is believed to be the major cause of the walking difficulty that results from such diseases.
The prospect of suppressing articular degeneration or destruction or of promoting chondrogenesis has been raised as a possible method of treating conditions such as chronic rheumatoid arthritis and osteoarthritis (J. Rheum. 22(1), Suppl. 43:136-139, 1995, Lab. Invest. 78(2):133-142).
Several different organism-derived substances and low molecular substances are known to have effects of promoting chondrogenesis or of inducing proliferation of chondrocytes. Substances that have been reported to have chondrogenesis-promoting effects include growth factors such as TGF-&bgr;, (Transforming growth factor &bgr;), BMP-2 (J. Bone Joint Surg. 79-A(10):1452-1463, 1997), concanavalin A which is a type of lectin (J. Biol. Chem., 265:10125-10131, 1990) and osteogenin (BMP-7), as well as low molecular substances such as vitamin D derivatives (1&agr;, 25-D
3
) (Cancer Res., 49:5435-5442, 1989), vitamin A derivatives (retinoic acid) (Dev. Biol., 130:767-773, 1988), vanadates (J. Cell Biol., 104:311-319, 1987), benzamides (J. Embryol. Exp. Morphol., 85:163-175, 1985), benzyl &bgr;-D-xyloside (Biochem. J., 224:977-988, 1984), triiodothyronines (T
3
) (Endocrinology, 111:462-468, 1982), prostaglandin derivatives (PGE2, U44069) (Prostaglandin, 19:391-406, 1980), dbcAMP (J. Cell. Physiol., 100:63-76, 1979) and 8-Br-cAMP(J. Cell. Physiol., 100:63-76, 1979).
Of these organism-derived substances and low molecular substances, TGF-&bgr;, holds the most promise as a useful treatment agent, and TGF-&bgr;
1
, which is one isoform of TGF-&bgr;, has been reported to promote chondrogenesis when intraarticularly administered (Lab. Invest. 71(2):279-290, 1994). Also, since TGF-&bgr;
1
suppresses arthritis-induced loss of proteoglycans in articular cartilage, or stated differently, it inhibits destruction of articular cartilage due to its anabolic effect on articular cartilage when administered intraarticularly in experimental animal models with induced arthritis, its possibility as a useful treatment agent for articular disease such as rheumatism has been suggested (Lab. Invest. 78(2):133-142, 1998).
However, even TGF-&bgr; which holds the most promise as a useful treatment agent has been reported to provoke synovitis even while promoting chondrogenesis, and this therefore poses a serious problem for its use as a treatment agent for articular diseases (Lab. Invest. 71(2):279-290, 1994), for which reason it has not been applied in the clinic as a treatment agent for such conditions. In summary, then, no practical treatment agent therapy exists that is based on promoting chondrogenesis.
DISCLOSURE OF THE INVENTION
It is an object of the present invention to overcome the aforementioned drawbacks of the prior art by providing a chondrogenesis promoter and cartilage repair agent that are able to promote chondrogenesis or induce proliferation of chondrocytes.
It is another object of the invention to provide a reagent with chondrogenesis promoting action which is useful for biological, physical or chemical research on cartilage.
It is yet another object of the invention to provide indolin-2-one derivatives that are useful as chondrogenesis promoters.
It is still yet another object of the invention to provide indolin-2-one derivatives that are useful as bone fracture repair promoters.
As a result of diligent research aimed at achieving these objects, the present inventors have completed the present invention upon the discovery that indolin-2-one derivatives having a specific structure exhibit a chondrogenesis promoting effect.
In other words, a chondrogenesis promoter according to the invention comprises as an active ingredient a compound represented by general formula (I) or a salt thereof:
wherein
R
1
represents a halogen atom, a lower alkyl group, a lower alkoxy group, a hydroxyl group, a nitro group, a trifluoromethyl group, a lower alkylthio group, an acyl group, a carboxyl group, a mercapto group or an amino group with an optional substituent;
R
2
represents a hydrogen atom, a lower alkyl group with an optional substituent, a lower alkenyl group with an optional substituent, a lower alkynyl group with an optional substituent, a lower alkoxy group with an optional substituent, an acyl group with an optional substituent, an aryl group with an optional substituent or a heterocyclic group with an optional substituent;
R
3
represents a lower alkyl group with an optional substituent, a cycloalkyl group with an optional substituent, an aryl group with an optional substituent or a heterocyclic group with an optional substituent;
R
4
represents a hydrogen atom, a lower alkyl group with an optional substituent, an aryl group with an optional substituent, a heterocyclic group with an optional substituent, —OR
5
, —SR
5
or —NR
6
R
7
wherein R
5
, R
6
and R
7
may be the same or different and each represents a hydrogen atom, a lower alkyl group with an optional substituent, a cycloalkyl group with an optional substituent, an aryl group with an optional substituent, a heterocyclic group with an optional substituent, a lower alkoxy group or an amino group with an optional substituent, and R
6
and R
7
may together form a group represented by —(CH
2
)
m
— or —(CH
2
)
1
NR
8
(CH
2
)
k
— wherein k, 1 and m each represent an integer of 1-8 and R
8
represents a hydrogen atom or a lower alkyl group;
X and Y may be the same or different and each represents —CH
2
—, —NH—or —O—, and n represents an integer of 0-4.
A cartilage repair agent according to the invention also comprises as an active ingredient a compound represented by general formula (I) above or a salt thereof.
A reagent for biological, physical or chemical research on cartilage according to the invention also comprises as an active ingredient a compound represented by general formula (I) above or a salt thereof.
An indolin-2-one derivative according to the invention is represented by the following general formula (IV):
wherein R
12
represents a lower alkyl group substituted at the same carbon with two lower alkoxy groups which is optionally substituted with 1-5 halogen atoms.
Also, R
12
of the indolin-2-one derivative according to the invention may be represented by general formula (V):
wherein R
13
and R
14
may be the same or different, and each represents a lower alkyl group which is optionally substituted with 1-5 halogen atoms.


REFERENCES:
patent: 5952511 (1999-09-01), Esaki et al.
patent: 6031111 (2000-02-01), Esaki et al.
patent: 7-048349 (1995-02-01),

Affiliated with

Also associated with

Rating

Chondrongenesis promotors and indolin-2-one derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chondrongenesis promotors and indolin-2-one derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chondrongenesis promotors and indolin-2-one derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2991662